IRINOTECAN INTAS irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial

Država: Australija

Jezik: engleski

Izvor: Department of Health (Therapeutic Goods Administration)

Aktivni sastojci:

irinotecan hydrochloride trihydrate, Quantity: 300 mg

Dostupno od:

Accord Healthcare Pty Ltd

Farmaceutski oblik:

Injection, concentrated

Sastav:

Excipient Ingredients: hydrochloric acid; sodium hydroxide; lactic acid; water for injections; sorbitol

Administracija rute:

Intravenous Infusion

Jedinice u paketu:

1

Tip recepta:

(S4) Prescription Only Medicine

Terapijske indikacije:

Irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Proizvod sažetak:

Visual Identification: A pale yellow clear solution; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Status autorizacije:

Registered

Datum autorizacije:

2020-03-05